Started since 1975, Japfa has grown from a single poultry feed mill in Indonesia to a notable agri-food company with a presence in five countries.
Continuous expansion into new geographies and other protein-related categories has allowed it to tap new growth opportunities and reduce market and protein risk. Its business is vertically integrated across the value chain from animal feed production to breeding and commercial farming.
Japfa’s primary animal proteins are poultry, swine and dairy. It is the second-largest feed producer in Indonesia and generates the highest milk yield in China.
The holding company, listed on the Singapore Exchange, holds a 52.4% stake in the Indonesia-listed PT Japfa TBK.
Refer to the 33-page PDF report attached for further details on company background and industry overview.
BUY for a free ride on segments that generate at least US$30m net profit a year.
Our SOTP-based target price provides 47.5% upside and implies 12.2x 2018F P/E, a 10.3% discount to peers’ 13.6x. Japfa Ltd (Japfa) is deeply undervalued.
Japfa’s 52.4% stake in the IDX-listed PT Japfa TBK alone is equivalent to 93% market cap of Japfa. It implies that Japfa’s three other business segments, which could generate at least US$30m net profit per year for 2018-20, are trading at 1.9x 2018F P/E.
Japfa is currently trading at 8.3x 2018F P/E, at a significant discount of 39% to peers in the market and a 17% discount to its 52.4%-owned subsidiary. This valuation gap should narrow as concerns over the earnings drag from other businesses eases.
Proxy to rising protein consumption from growing middle class.
Japfa operates in some of the most populous emerging economies in Asia that cumulatively house around three billion people or 40% of the world’s population.
According to the Organisation for Economic Co-operation and Development (OECD), levels of meat consumption in these markets, while growing fast, are still far below levels in developed markets and global averages. For example, Indonesia’s annual meat consumption in 2016 was at only 11kg/capita vs the global average of 34kg/capita.
On a strong turnaround path from 2018 onwards.
2017 saw a perfect storm with a weak poultry performance in Indonesia due to sluggish consumption and China’s ban on pork imports from Vietnam. The likelihood of multiple adverse factors across countries occurring simultaneously again seems remote.
We expect 2018 to be a mean reversion year with core profit growing > 500% y-o-y, back to 2015-16 levels.
Established and diversified business model not fully appreciated.
We think the market does not fully understand Japfa’s established business model, as:
To better understand the business, we performed detailed studies on PT Japfa TBK, which contributes 69% of our 2018F profit forecast and has been listed on the IDX since 1989. Its financial performance for the past 15 years shows that the business is resilient.
Initiate coverage with BUY and SOTP-based target price of S$0.90.
Japfa’s stub value excluding its 52.4% subsidiary stake in the IDX-listed PT Japfa TBK implies that Japfa’s three other business segments, which could generate at least US$30m net profit for 2018-20F per year are trading at 2.4x 2018F P/E.
Japfa is currently trading at 8.3x 2018F P/E, a significant discount of 39% to peers and a 17% discount to its 52.4%-owned subsidiary. This valuation gap should narrow as the concerns over the earnings drag from other businesses eases.
Our forecasts and target price are conservative vs 1H18 results and consensus.
Compared to 1H18’s core net profit of US$67m, our 2018 forecast of US$101m is considered conservative as we provide a wide margin of error for any major swings in animal protein prices. In addition, our net profit forecast and P/E valuation basis for PT Japfa TBK are conservative compared to the street’s.
Our 2018 and 2019 net profit forecasts for PT Japfa TBK are 8% and 17% below consensus, while our valuation multiple of 12.9x 2018F P/E multiple is also below consensus’ 14.7x. If we were to adopt consensus forecast and valuation multiple, our SOTP target price will increase 9% to S$0.98.
At this point, we think there could be upside to our net profit forecasts as the prices of three key proteins:
We value Japfa on a SOTP methodology, based on ascribed P/E multiples for its key business segments, which include:
Our target price after incorporating a 10% holding company discount is at S$0.90, which implies 12.2x 2018F P/E, a 10.3% discount to peers’ 13.6x. We believe the market has yet to fully understand and appreciate Japfa’s diversified business model due to several factors, such as complexity of the business, thin broker coverage, short listing history and short track record of earnings. Refer to the 33-page PDF report attached for complete valuation details.
We believe the valuation gap should narrow as the market concerns will be addressed, when losses from smaller segments reverse.
Details of our SOTP valuation methodology for each business segment:
Source: UOB Kay Hian Research - 17 Oct 2018
Chart | Stock Name | Last | Change | Volume |
---|